Stocks
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -233.8% | -224.6% | -789.5% | -864.5% | -1 396% | -1 124% | ||
| Changes by years, y/y, % | +65pp | +9pp | -565pp | -75pp | -531pp | +36.1% | |||
Intellia Therapeutics. EBITDA margin, %
Intellia Therapeutics. EBITDA margin, changes, pp
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | -1 074% | -7 169% | -385.3% | -1 961% | -1 560% | -1 124% | |
| Changes by years, y/y, % | -352pp | -6 398pp | +502pp | -988pp | -486pp | |||
| Changes by quarters, q/q, % | -101pp | -6 095pp | +6 783pp | -1 576pp | +401pp | |||
